On November 5, 2026, Annovis Bio, Inc. completed a public offering generating gross proceeds of approximately $21 million. The offering included 19 million shares of common stock and accompanying warrants. In addition, a company director participated by purchasing 5 million shares and accompanying warrants for $5 million.
Who to call at Annovis Bio, and when
A new round usually means Annovis Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Annovis Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Annovis Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Annovis Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Annovis Bio
Location
101 Lindenwood Dr. , Suite #225
Berwyn, Pennsylvania, United States
About
Annovis Bio is pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Annovis Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BerwynBiotechnologyHealthcare